| Heading: |
Medical Treatments |
| Question ID: |
1790178 |
| UIN: |
HL6291 |
| House: |
Lords |
| Date tabled: |
2025-03-28 |
| Asking Member ID: |
4719 |
| Asking Member display name: |
Baroness Bennett of Manor Castle
|
| Asking Member handle: |
natalieben
|
| Asking Member Twitter reference: |
@natalieben
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what plans they have to manage the NHS provision of biologic medications and other high-cost treatments, particularly to avoid inequality between patients under different integrated care boards. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-07 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service in England on whether new medicines, including biologics, should be routinely funded by the NHS based on an assessment of the... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |